Abogen signs up to $7.8 billion Novartis RNA therapy deal
Abogen said it signed a licensing deal worth up to $7.8 billion with Novartis to develop an RNA-based therapy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.